Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;pers:(Wallin Anders 1950);pers:(Blennow Kaj 1958);pers:(Hansson Oskar)"

Sökning: LAR1:gu > Wallin Anders 1950 > Blennow Kaj 1958 > Hansson Oskar

  • Resultat 1-8 av 8
Sortera/gruppera träfflistan
  • Andersson, Malin E, 1978-, et al. (författare)
  • Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease.
  • 2007
  • Ingår i: International journal of molecular medicine. - 1107-3756. ; 20:2, s. 233-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Kinesin is a microtubule-associated motor protein that transports Alzheimer-associated amyloid precursor protein (APP) in neurons. In animal models, impaired kinesin-mediated APP transport seems to enhance formation of the neurotoxic 42 amino acid fragment of beta-amyloid (A beta 42). In man, one study suggests that a polymorphism (rs8702, 56,836G > C) in the kinesin light chain 1 gene (KNS2) may affect the risk of Alzheimer's disease (AD). To further assess KNS2 as a susceptibility gene for AD we analyzed 802 patients with sporadic AD and 286 controls, 134 longitudinally followed patients with mild cognitive impairment (MCI) and 39 cognitively stable controls for the rs8702 polymorphism. The rs8702 polymorphism did not influence risk of AD (p=0.46). However, rs8702 interacted with APOE epsilon 4 carrier status in AD (p=0.006) and influenced cerebrospinal fluid levels of hyper-phosphorylated tau in MCI patients who converted to AD during follow-up (p=0.018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis.
  • Brinkmalm-Westman, Ann, 1966-, et al. (författare)
  • SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease
  • 2014
  • Ingår i: Molecular Neurodegeneration. - BioMed Central. - 1750-1326. ; 9, s. 53
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Synaptic degeneration is an early pathogenic event in Alzheimer's disease, associated with cognitive impairment and disease progression. Cerebrospinal fluid biomarkers reflecting synaptic integrity would be highly valuable tools to monitor synaptic degeneration directly in patients. We previously showed that synaptic proteins such as synaptotagmin and synaptosomal-associated protein 25 (SNAP-25) could be detected in pooled samples of cerebrospinal fluid, however these assays were not sensitive enough for individual samples. Results: We report a new strategy to study synaptic pathology by using affinity purification and mass spectrometry to measure the levels of the presynaptic protein SNAP-25 in cerebrospinal fluid. By applying this novel affinity mass spectrometry strategy on three separate cohorts of patients, the value of SNAP-25 as a cerebrospinal fluid biomarker for synaptic integrity in Alzheimer's disease was assessed for the first time. We found significantly higher levels of cerebrospinal fluid SNAP-25 fragments in Alzheimer's disease, even in the very early stages, in three separate cohorts. Cerebrospinal fluid SNAP-25 differentiated Alzheimer's disease from controls with area under the curve of 0.901 (P < 0.0001). Conclusions: We developed a sensitive method to analyze SNAP-25 levels in individual CSF samples that to our knowledge was not possible previously. Our results support the notion that synaptic biomarkers may be important tools for early diagnosis, assessment of disease progression, and to monitor drug effects in treatment trials.
  • Johansson, Per, 1966-, et al. (författare)
  • Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women.
  • 2011
  • Ingår i: Clinical endocrinology. - 1365-2265. ; 75:3, s. 301-308
  • Tidskriftsartikel (refereegranskat)abstract
    • Context: Sex steroid levels decrease with increasing age, but little is known whether this is of importance for the age-related decline in cognitive function. Design and Patients: A cross-sectional study of 50 (26 men) consecutive patients under primary evaluation of cognitive impairment (D group) and 18 (9 men) matched healthy controls (C group). Measurements: Sex steroid and precursor levels were determined in serum and when measurable, in cerebrospinal fluid (CSF) using gas chromatography/mass spectroscopy (GC-MS) or liquid chromatography/mass spectroscopy (LC-MS). Sex hormone binding globulin (SHBG) and cortisol concentrations were measured using conventional assays. Results: Patients in the D group had higher 24-h urine cortisol level and increased serum levels of dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS, androsterone (ADT), and estrone (E1) and its sulfate ester E1S, compared to the controls. When men and women were analyzed separately, increased serum concentrations of E1 and E1S were observed in both D men and D women whereas increased levels of other sex steroids and cortisol were seen only in D women. Conclusions: In both D men and women, serum E1 and E1S levels were increased whereas other changes were gender-specific and only seen in D women. Further studies are needed to determine whether these changes are a cause of, or merely a consequence of, cognitive impairment in elderly subjects.
  • Johansson, Per, 1966-, et al. (författare)
  • Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease.
  • 2013
  • Ingår i: Psychoneuroendocrinology. - 1873-3360. ; 38:7
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Little is known of the association between thyroid hormones in the central nervous system and Alzheimer's disease (AD). We determined thyroid hormone levels in serum and cerebrospinal fluid (CSF) in a well-defined homogeneous mono-center population. Methods: Fifty-nine consecutive patients under primary evaluation for cognitive impairment were recruited. The participants included patients with AD or mild cognitive impairment (MCI) diagnosed with AD upon follow-up (n = 31), patients with stable MCI (SMCI, n = 13), patients with other dementias (n = 15), and healthy controls (n = 19). Thyroid hormones in serum and CSF and AD biomarkers in CSF were analyzed using established immunochemical assays. Cognitive impairment was estimated using mini-mental state examination (MMSE). Results: Serum levels of free and total thyroxine (T4) and triiodothyronine (T3) were similar in all groups whereas a marginal increase in serum thyroid-stimulating hormone (TSH) level was observed in the AD patients. The CSF level of total T4 was decreased in patients with AD and other dementias compared to SMCI (both P = 0.01) and healthy controls (both P = 0.001), whereas CSF levels of TSH and total T3 were unchanged. In the total study population, CSF total 14 level correlated positively with MMSE score (r = 0.26, P < 0.05) and negatively with CSF total-tau (T-Tau) level (r = -0.23, P < 0.05). Conclusion: Patients with AD as well as other dementias had signs of mild brain hypothyroidism, which could only to a small extent be detected in serum values. (C) 2012 Elsevier Ltd. All rights reserved.
  • Mattsson, Niklas, 1979-, et al. (författare)
  • Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility.
  • 2011
  • Ingår i: Neuromolecular medicine. - 1559-1174. ; 13:2, s. 151-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Activated microglial cells, which are the resident macrophages of the central nervous system, surround amyloid beta-plaques in Alzheimer's disease (AD) brains. Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells. We therefore examined cerebrospinal fluid (CSF) biomarkers in patients with AD, other dementias, mild cognitive impairment and in healthy controls. Samples were analyzed for markers with known association to macrophage activity, including chitotriosidase, YKL-40 (CHI3L1, HC gp-39) and chemokine CC motif ligand 2 (CCL2, MCP1). Patients with AD had higher chitotriosidase activity than controls and patients with stable mild cognitive impairment, consistent with the presence of activated microglial cells in AD brains, but with large overlaps between groups. CCL2 and YKL-40 concentrations did not differ among groups. Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology.
  • Mattsson, Niklas, 1979-, et al. (författare)
  • Converging pathways of chromogranin and amyloid metabolism in the brain.
  • 2010
  • Ingår i: Journal of Alzheimer's disease : JAD. - 1875-8908. ; 20:4, s. 1039-49
  • Tidskriftsartikel (refereegranskat)abstract
    • Much is unknown regarding the regulation of Alzheimer-related amyloid-beta protein precursor (A beta PP)-processing in the human central nervous system. It has been hypothesized that amyloidogenic A beta PP-processing preferentially occurs in the regulated secretory pathway of neurons. To test this hypothesis we looked for correlations of A beta PP-derived molecules in cerebrospinal fluid (CSF) with chromogranin (Cg) derived peptides, representing the regulated secretion. Patients with Alzheimer's disease (AD, N = 32), multiple sclerosis (MS, N = 50), and healthy controls (N = 70) were enrolled. CSF was analyzed for the amyloid peptides A beta(1-42), A beta(x-42), A beta(x-40), A beta(x-38), alpha-cleaved soluble A beta PP (sA beta PP alpha), beta-cleaved soluble A beta PP (sA beta PP beta), and peptides derived from CgB and SgII (Secretogranin-II, CgC). We investigated CSF levels of the protease BACE1, which processes A beta PP into A beta, in relation to Cg-levels. Finally, we measured Cg levels in cell media from untreated and BACE1-inhibited SH-SY5Y human neuroblastoma cells. CSF Cg levels correlated to sA beta PP and A beta peptides in AD, MS, and controls, and to CSF BACE1. Cell medium from BACE1-inhibited cells had decreased CgB levels. These results suggest that a large part of A beta PP in the human central nervous system is processed in the regulated secretory pathway of neurons.
  • Movérare-Skrtic, Sofia, 1976-, et al. (författare)
  • Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study.
  • 2012
  • Ingår i: Experimental gerontology. - 1873-6815. ; 47:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Leukocyte telomere length (LTL) is associated with the aging process and may be related to cognitive aging. Previous studies have shown conflicting results whether LTL is affected in patients with Alzheimer's disease (AD). In this pilot study, we investigated LTL in a well-defined homogeneous mono-center population. Sixty consecutive patients admitted for cognitive impairment to a memory clinic were recruited. The participants included patients with AD or mild cognitive impairment (MCI) diagnosed with AD upon follow-up (n=32), patients with stable MCI (n=13), patients with other dementias diagnosed at primary evaluation or upon follow-up (n=15), and healthy controls (n=20). LTL was determined using a quantitative PCR assay. Patients with AD had similar LTL as healthy controls. Patients with stable MCI had reduced LTL both compared to AD patients (p=0.02) and controls (p=0.008). Subanalyses within the AD group showed that patients with MCI that later converted to AD had similar LTL as patients with clinical diagnosis of AD at primary evaluation and healthy controls whereas the LTL was longer compared to the stable MCI group (p=0.02). There were no correlations between LTL and the core AD biomarkers A beta(1-42), T-tau and P-tau. In conclusion, in this pilot study, patients with AD or MCI that later converted to AD had similar LTL as healthy controls. Patients with stable MCI that did not progress to dementia had reduced LTL compared to controls, which might suggest a more marked biological aging as a cause of the cognitive symptoms in this group. (C) 2011 Elsevier Inc. All rights reserved.
  • Rosén, Christoffer, 1986-, et al. (författare)
  • Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases.
  • 2011
  • Ingår i: Frontiers in aging neuroscience. - 1663-4365. ; 3
  • Tidskriftsartikel (refereegranskat)abstract
    • The role of biomarkers in neurodegenerative diseases has been emphasized by recent research. Future clinical demands for identifying diseases at an early stage may render them essential. The aim of this pilot study was to test the analytical performance of two multiplex assays of cerebral markers on a well-defined clinical material consisting of patients with various neurodegenerative diseases. We measured 10 analytes in plasma and cerebrospinal fluid (CSF) from 60 patients suffering from Alzheimer's disease (AD), vascular dementia, frontotemporal dementia, dementia with Lewy bodies, or mild cognitive impairment, as well as 20 cognitively healthy controls. We used the Randox biochip-based Evidence Investigator™ system to measure the analytes. We found it possible to measure most analytes in both plasma and CSF, and there were some interesting differences between the diagnostic groups, although with large overlaps. CSF heart-type fatty acid-binding protein was increased in AD. Glial fibrillary acidic protein and neutrophil gelatinase-associated lipocalin in CSF and D-dimer in plasma were elevated in patients with cerebrovascular disease. A multivariate statistical analysis revealed that the pattern of analytes could help to differentiate the conditions, although more studies are required to verify this.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-8 av 8
fritt online (1)
Typ av publikation
tidskriftsartikel (8)
Typ av innehåll
refereegranskat (8)
Zetterberg, Henrik, ... (8)
Mattsson, Niklas, 19 ... (6)
Johansson, Per, 1966 ... (6)
visa fler...
Svensson, Johan, 196 ... (5)
Johansson, Jan-Ove, ... (5)
Andreasson, Ulf, 196 ... (3)
Minthon, Lennart (1)
Brinkmalm-Westman, A ... (1)
Brinkmalm, Gunnar, (1)
Olsson, Maria, (1)
Andersen, Oluf, 1941 ... (1)
Haghighi, Sara, (1)
Olsson, Bob, 1969-, (1)
Stridsberg, Mats, (1)
Ohlsson, Claes, 1965 ... (1)
Månsson, Jan-Eric, 1 ... (1)
Bogdanovic, Nenad (1)
Movérare-Skrtic, Sof ... (1)
Svensson, Johan, (1)
Almqvist, Erik G. (1)
Andreasen, Niels (1)
Andersson, Malin E, ... (1)
Sjölander, Annica, 1 ... (1)
Minthon, Lennart, 19 ... (1)
Jern, Christina, 196 ... (1)
Jood, Katarina, 1966 ... (1)
Sjolander, Annica (1)
Movérare-Skrtic, Sof ... (1)
Mansson, Jan-Eric (1)
Frölich, Lutz (1)
Labrie, Fernand (1)
Öhrfelt, Annika, 197 ... (1)
Brinkmalm, Ann (1)
Ohrfelt, Annika (1)
Honer, William G (1)
Hausner, Lucrezia (1)
Frolich, Lutz (1)
Lamont, John, (1)
Johansson, Jan-Ove (1)
Tabatabaei, Shahrzad ... (1)
Hansson, Oskar, 1960 ... (1)
Rosén, Christoffer, ... (1)
visa färre...
Göteborgs universitet (8)
Lunds universitet (8)
Uppsala universitet (1)
Karolinska Institutet (1)
Engelska (8)
Ämne (HSV)
Medicin och hälsovetenskap (8)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy